Filter by Tag
Introducing BPaL: Experiences from countries supported under the LIFT-TB project
Publication: PLOS One
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis
Publication: New England Journal of Medicine
Early-phase and preclinical studies suggest that moxifloxacin-containing regimens could allow for effective 4-month treatment of…
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis
Publication: PLoS One
Clofazimine pharmacokinetics in patients with TB: dosing implications
Publication: Journal of Antimicrobial Chemotherapy
Clofazimine is in widespread use as a key component of drug-resistant TB regimens, but the…
Savings from the introduction of BPaL and BPaLM regimens at the country level
Publication: IJTLD Open
Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan
Publication: Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Cost and cost-effectiveness of BPaL regimen used in drug-resistant TB treatment in the Philippines
Publication: The International Journal of Tuberculosis and Lung Disease
Prevalence and genetic basis of Mycobacterium tuberculosis resistance to pretomanid in China
Publication: Annals of Clinical Micobiology and Antimicrobials
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Publication: Lancet Infectious Diseases